No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
0.12% saline |
- |
- |
- |
- |
1件: 299 |
2 |
0.9% isotonic saline (is) |
- |
- |
- |
- |
1件: 299 |
3 |
0.9% isotonic saline (is), 4ml |
- |
- |
- |
- |
1件: 299 |
4 |
0.9% w/v sodium chloride solution |
Sodium chloride |
D02056 |
- |
- |
1件: 299 |
5 |
033841 |
- |
- |
- |
- |
1件: 299 |
6 |
1,5 (butylimino)-1,5-dideoxy-d-glucitol |
Sorbitol |
D00096 |
- |
- |
1件: 299 |
7 |
1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline carboxylic acid |
- |
- |
- |
- |
1件: 299 |
8 |
100 mg vx-445/50 mg tez /75 mg iva fdc |
- |
- |
- |
- |
1件: 299 |
9 |
100 mg/m2 dose |
- |
- |
- |
- |
1件: 299 |
10 |
2% chlorhexidine solution wipes |
Chlorhexidine |
D00858, D01345, D03463, D07668 |
- |
- |
1件: 299 |
11 |
200 mg/m2 dose |
- |
- |
- |
- |
1件: 299 |
12 |
25-hydroxyvitamin d3 |
Calcifediol |
D00122 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 299 |
13 |
291844 |
- |
- |
- |
- |
2件: 246, 299 |
14 |
4% chlorhexidine gluconate liquid skin cleanser |
Chlorhexidine |
D00858, D01345, D03463, D07668 |
- |
- |
1件: 299 |
15 |
4-phenylbutyrate |
Phenylbutyric acid |
D05868 |
- |
- |
2件: 251, 299 |
16 |
4.2% nacl/inhalation solution |
- |
- |
- |
- |
1件: 299 |
17 |
5-methyltetrahydrofolate and vitamin b12 |
Cyanocobalamin |
D00166, D03615, D03616, D03617 |
- |
- |
1件: 299 |
18 |
5000 iu of cholecalciferol |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 299 |
19 |
552-02 |
- |
- |
- |
- |
2件: 53, 299 |
20 |
6% hypertonic saline (hs), 4ml |
- |
- |
- |
- |
1件: 299 |
21 |
7% hypertonic saline (hs) |
- |
- |
- |
- |
1件: 299 |
22 |
7% nacl |
- |
- |
- |
- |
1件: 299 |
23 |
7% saline |
- |
- |
- |
- |
1件: 299 |
24 |
Aac hexal |
- |
- |
- |
- |
1件: 299 |
25 |
Abbv-2222 |
- |
- |
- |
- |
1件: 299 |
26 |
Abbv-3067 |
- |
- |
- |
- |
1件: 299 |
27 |
Abelcet |
Amphotericin b |
D00203 |
- |
- |
1件: 299 |
28 |
Acc600tabs |
- |
- |
- |
- |
1件: 299 |
29 |
Acebilustat |
Acebilustat |
- |
- |
- |
1件: 299 |
30 |
Acetate |
Acetate |
- |
- |
- |
40件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
31 |
Acetylcysteine |
Acetylcysteine |
D00221 |
- |
- |
14件: 6, 13, 19, 20, 49, 51, 58, 85, 94, 111, 164, 233, 298, 299 |
32 |
Acetylcysteine sodium |
Acetylcysteine |
D00221 |
- |
- |
1件: 299 |
33 |
Active treatment group 7% hypertonic saline |
- |
- |
- |
- |
1件: 299 |
34 |
Actrapid 100 iu/ml, solution for injection in a vial |
- |
- |
- |
- |
1件: 299 |
35 |
Actrapid penfill 100ui/ml |
- |
- |
- |
- |
1件: 299 |
36 |
Acute (1 hour) sildenafil |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 299 |
37 |
Acute antioxidant |
- |
- |
- |
- |
1件: 299 |
38 |
Adempas |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
4件: 51, 86, 225, 299 |
39 |
Adempas 0.125 mg |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 299 |
40 |
Adempas 0.5 mg |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
2件: 86, 299 |
41 |
Adempas 1.0 mg |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
2件: 86, 299 |
42 |
Adempas 2.0 mg |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
2件: 86, 299 |
43 |
Adeno-associated virus-cftr vector |
- |
- |
- |
- |
1件: 299 |
44 |
Advagraf prolonged-release hard capsules |
Tacrolimus |
D00107, D08556 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
1件: 299 |
45 |
Aer002 |
- |
- |
- |
- |
1件: 299 |
46 |
Aerosolized, human, plasma-derived alpha-1 antitrypsin |
- |
- |
- |
- |
1件: 299 |
47 |
Aerosoltherapy |
- |
- |
- |
- |
1件: 299 |
48 |
Aerovanc |
- |
- |
- |
- |
1件: 299 |
49 |
Air dnase |
- |
- |
- |
- |
1件: 299 |
50 |
Air dnase™ |
- |
- |
- |
- |
1件: 299 |
51 |
Ajulemic acid |
Ajulemic acid |
D11312 |
1件: CNR2 |
1件: Neuroactive ligand-receptor interaction |
3件: 50, 51, 299 |
52 |
Alanine |
L-alanine |
D00012 |
- |
- |
3件: 13, 298, 299 |
53 |
Albuterol |
Salbutamol |
D02147 |
1件: ADRB2 |
8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
8件: 12, 13, 86, 89, 113, 231, 256, 299 |
54 |
Albuterol inhaler. |
Salbutamol |
D02147 |
1件: ADRB2 |
8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
2件: 231, 299 |
55 |
Alendronate |
Alendronic acid |
D00939, D07119 |
1件: FDPS |
4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
7件: 19, 41, 46, 50, 271, 274, 299 |
56 |
Alendronate sodium |
Alendronic acid |
D00939, D07119 |
1件: FDPS |
4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
2件: 19, 299 |
57 |
Alginate |
Alginic acid |
D02324 |
- |
- |
2件: 53, 299 |
58 |
Alginate oligosaccharide |
Alginic acid |
D02324 |
- |
- |
1件: 299 |
59 |
Allo-hmscs |
- |
- |
- |
- |
2件: 211, 299 |
60 |
Alpha-1 hc 100 mg |
- |
- |
- |
- |
1件: 299 |
61 |
Alpha-1 hc 200 mg |
- |
- |
- |
- |
1件: 299 |
62 |
Alpha1-proteinase inhibitor |
Alpha-1-proteinase inhibitor |
- |
- |
- |
2件: 231, 299 |
63 |
Alpha1-proteinase inhibitor (human) |
Alpha-1-proteinase inhibitor |
- |
- |
- |
2件: 231, 299 |
64 |
Altu-135 |
- |
- |
- |
- |
1件: 299 |
65 |
Alx-009 |
- |
- |
- |
- |
1件: 299 |
66 |
Amikacin |
Amikacin |
D00865, D02543 |
- |
- |
2件: 60, 299 |
67 |
Amikacin nebulization |
Amikacin |
D00865, D02543 |
- |
- |
1件: 299 |
68 |
Amikacine |
Amikacin |
D00865, D02543 |
- |
- |
1件: 299 |
69 |
Amikacine nebulization |
Amikacin |
D00865, D02543 |
- |
- |
1件: 299 |
70 |
Amikin, amiklin, amicacin, bb-k8, biklin, fabianol, kaminax, mikavir, novamin, pierami |
Amikacin |
D00865, D02543 |
- |
- |
1件: 299 |
71 |
Amikin®, amiklin, amicacin, bb-k8, biklin®, fabianol®, kaminax, mikavir, novamin®, pierami |
Amikacin |
D00865, D02543 |
- |
- |
1件: 299 |
72 |
Amiklin |
Amikacin |
D00865, D02543 |
- |
- |
1件: 299 |
73 |
Amiloride |
Amiloride |
D00649, D07447 |
3件: SCNN1A, SCNN1B, SCNN1G |
2件: Aldosterone-regulated sodium reabsorption, Taste transduction |
3件: 13, 225, 299 |
74 |
Amiloride hcl |
Amiloride |
D00649, D07447 |
3件: SCNN1A, SCNN1B, SCNN1G |
2件: Aldosterone-regulated sodium reabsorption, Taste transduction |
1件: 299 |
75 |
Amiloride solution for inhalation |
Amiloride |
D00649, D07447 |
3件: SCNN1A, SCNN1B, SCNN1G |
2件: Aldosterone-regulated sodium reabsorption, Taste transduction |
1件: 299 |
76 |
Amitriptylin |
Amitriptyline |
D00809, D07448 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
1件: 299 |
77 |
Amitriptylin-ct |
Amitriptyline |
D00809, D07448 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
1件: 299 |
78 |
Amitriptylin-ct tabletten |
Amitriptyline |
D00809, D07448 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
1件: 299 |
79 |
Amitriptyline |
Amitriptyline |
D00809, D07448 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
3件: 78, 226, 299 |
80 |
Amphotericin b |
Amphotericin b |
D00203 |
- |
- |
1件: 299 |
81 |
Amylase |
- |
- |
- |
- |
1件: 299 |
82 |
Anakinra |
Anakinra |
D02934 |
2件: IL1R1, IL1R2 |
15件: Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer |
15件: 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 84, 86, 106, 107, 299 |
83 |
Andecaliximab |
- |
- |
- |
- |
3件: 46, 96, 299 |
84 |
Anti-pseudomonas igy gargle |
- |
- |
- |
- |
1件: 299 |
85 |
Anti-reflux pharmacotherapy |
- |
- |
- |
- |
1件: 299 |
86 |
Antibiotic |
Bacitracin |
D00128, D03047, D03048 |
- |
- |
1件: 299 |
87 |
Antioxidant cocktail |
- |
- |
- |
- |
1件: 299 |
88 |
Aquadek |
- |
- |
- |
- |
1件: 299 |
89 |
Aquadeks-2 |
- |
- |
- |
- |
1件: 299 |
90 |
Ard-3150 |
- |
- |
- |
- |
1件: 299 |
91 |
Arginine |
L-arginine |
D02982 |
- |
- |
5件: 67, 78, 113, 251, 299 |
92 |
Arikace |
- |
- |
- |
- |
1件: 299 |
93 |
Arikace™ |
- |
- |
- |
- |
1件: 299 |
94 |
Arikayce™ |
- |
- |
- |
- |
1件: 299 |
95 |
Aspartate |
Aspartic acid |
D00013 |
- |
- |
3件: 13, 75, 299 |
96 |
Ataluren |
Ataluren |
D09323 |
- |
- |
6件: 19, 113, 140, 246, 299, 329 |
97 |
Ataluren (ptc124) |
Ataluren |
D09323 |
- |
- |
2件: 113, 299 |
98 |
Ataluren (ptc124®) |
Ataluren |
D09323 |
- |
- |
1件: 299 |
99 |
Atorvastatin |
Atorvastatin |
D00258, D00887, D07474 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
17件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 160, 222, 225, 265, 271, 299 |
100 |
Aurexis® (tefibazumab) |
- |
- |
- |
- |
1件: 299 |
101 |
Avian polyclonal igy antibody against pa |
- |
- |
- |
- |
1件: 299 |
102 |
Avibactam |
Avibactam |
- |
- |
- |
1件: 299 |
103 |
Azd1236 |
Azd1236 |
- |
- |
- |
1件: 299 |
104 |
Azd5634 |
- |
- |
- |
- |
1件: 299 |
105 |
Azd5634 for infusion |
- |
- |
- |
- |
1件: 299 |
106 |
Azd5634 for inhalation |
- |
- |
- |
- |
1件: 299 |
107 |
Azd9668 |
- |
- |
- |
- |
1件: 299 |
108 |
Azithromycin |
Azithromycin |
D02134, D06390, D07486 |
- |
- |
6件: 13, 84, 85, 96, 228, 299 |
109 |
Azithromycin 250 mg tablets |
Azithromycin |
D02134, D06390, D07486 |
- |
- |
1件: 299 |
110 |
Azithromycin 500 mg film-coated tablet |
Azithromycin |
D02134, D06390, D07486 |
- |
- |
1件: 299 |
111 |
Azithromycin dihydrate |
Azithromycin |
D02134, D06390, D07486 |
- |
- |
2件: 228, 299 |
112 |
Azli |
- |
- |
- |
- |
1件: 299 |
113 |
Azli 75 mg three times a day (tid) |
- |
- |
- |
- |
1件: 299 |
114 |
Azli 75 mg three times daily (tid) |
- |
- |
- |
- |
1件: 299 |
115 |
Azli 75 mg two times a day (bid)/ three times a day (tid) |
- |
- |
- |
- |
1件: 299 |
116 |
Azli 75 mg two times a day (bid)/three times a day (tid) |
- |
- |
- |
- |
1件: 299 |
117 |
Aztreonam |
Aztreonam |
D00240, D06558 |
- |
- |
2件: 228, 299 |
118 |
Aztreonam for inhalation (ai) |
Aztreonam |
D00240, D06558 |
- |
- |
1件: 299 |
119 |
Aztreonam for inhalation solution (azli) |
Aztreonam |
D00240, D06558 |
- |
- |
1件: 299 |
120 |
Aztreonam lysine |
Aztreonam |
D00240, D06558 |
- |
- |
1件: 299 |
121 |
Aztreonam lysine for inhalation |
Aztreonam |
D00240, D06558 |
- |
- |
1件: 299 |
122 |
Balance |
Isoxaflutole |
- |
- |
- |
8件: 5, 6, 13, 18, 81, 113, 149, 299 |
123 |
Bay 85-8501 |
- |
- |
- |
- |
1件: 299 |
124 |
Bay q 3939 |
- |
- |
- |
- |
1件: 299 |
125 |
Bay63-2521 |
- |
- |
- |
- |
3件: 51, 86, 299 |
126 |
Bayq3939 |
- |
- |
- |
- |
1件: 299 |
127 |
Bb-k8 |
Amikacin |
D00865, D02543 |
- |
- |
1件: 299 |
128 |
Beta-adrenergic cocktail |
- |
- |
- |
- |
1件: 299 |
129 |
Bethkis |
Tobramycin |
D00063, D02542 |
- |
- |
1件: 299 |
130 |
Bh4 20mg |
- |
- |
- |
- |
1件: 299 |
131 |
Bh4 5mg |
- |
- |
- |
- |
1件: 299 |
132 |
Bi 1265162 |
- |
- |
- |
- |
1件: 299 |
133 |
Bi 443651 |
- |
- |
- |
- |
1件: 299 |
134 |
Biaxin ( clarithromycin) |
Clarithromycin |
D00276 |
- |
- |
1件: 299 |
135 |
Biil 283 bs (amelubent) |
- |
- |
- |
- |
1件: 299 |
136 |
Biil 284 bs, high dose |
- |
- |
- |
- |
1件: 299 |
137 |
Biil 284 bs, high dose, adult patients |
- |
- |
- |
- |
1件: 299 |
138 |
Biil 284 bs, high dose, pediatric patients |
- |
- |
- |
- |
1件: 299 |
139 |
Biil 284 bs, low dose |
- |
- |
- |
- |
1件: 299 |
140 |
Biil 284 bs, low dose, adult patients |
- |
- |
- |
- |
1件: 299 |
141 |
Biil 284 bs, low dose, pediatric patients |
- |
- |
- |
- |
1件: 299 |
142 |
Biil 284 bs, medium dose, adult patients |
- |
- |
- |
- |
1件: 299 |
143 |
Biil 284 bs, medium dose, pediatric patients |
- |
- |
- |
- |
1件: 299 |
144 |
Bio-25 probiotic |
- |
- |
- |
- |
1件: 299 |
145 |
Bisphosphonate treatment |
- |
- |
- |
- |
2件: 113, 299 |
146 |
Blood sample |
- |
- |
- |
- |
12件: 8, 13, 46, 49, 51, 53, 61, 66, 97, 274, 288, 299 |
147 |
Blood test |
- |
- |
- |
- |
5件: 36, 86, 113, 162, 299 |
148 |
Boost vhc |
- |
- |
- |
- |
1件: 299 |
149 |
Boots high strength garlic odour controlled |
Garlic |
- |
- |
- |
1件: 299 |
150 |
Bramitob |
- |
- |
- |
- |
1件: 299 |
151 |
Bramitob 300mg/4ml nebuliser solution |
- |
- |
- |
- |
1件: 299 |
152 |
Bramitob*nebul 28f 300mg/4ml |
- |
- |
- |
- |
1件: 299 |
153 |
Bramitob*nebul 56f 300mg/4ml |
- |
- |
- |
- |
1件: 299 |
154 |
Bramitob® administered by pari eflow® rapid electronic nebulizer |
- |
- |
- |
- |
1件: 299 |
155 |
Bramitob® administered by pari lc® plus nebulizer |
- |
- |
- |
- |
1件: 299 |
156 |
Broccoli |
Broccoli |
- |
- |
- |
2件: 36, 299 |
157 |
Broccoli sprouts |
Broccoli |
- |
- |
- |
1件: 299 |
158 |
Bronchitol |
Mannitol |
D00062 |
- |
- |
1件: 299 |
159 |
Bucelipase alfa |
- |
- |
- |
- |
1件: 299 |
160 |
Budesonide |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
9件: 66, 93, 94, 95, 96, 97, 98, 228, 299 |
161 |
Budesonide-formoterol single inhaler |
Budesonide, Formoterol |
D00246, D01373, D05277, D07990 |
2件: ADRB2, NR3C1 |
8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 299 |
162 |
Burlulipase |
Burlulipase |
- |
- |
- |
1件: 299 |
163 |
Calcium |
Calcium |
- |
- |
- |
24件: 6, 13, 19, 46, 49, 51, 65, 68, 75, 79, 84, 93, 94, 95, 96, 97, 214, 215, 222, 224, 235, 265, 298, 299 |
164 |
Calcium carbonate |
Calcium carbonate |
D00932, D10802 |
- |
- |
7件: 13, 19, 46, 75, 96, 235, 299 |
165 |
Calfactant |
Calfactant |
D03317 |
- |
- |
1件: 299 |
166 |
Carbonate |
Carbonate ion |
- |
- |
- |
10件: 2, 13, 17, 19, 46, 75, 96, 127, 235, 299 |
167 |
Cavosonstat |
Cavosonstat |
D10916 |
- |
- |
1件: 299 |
168 |
Cayston |
Aztreonam |
D00240, D06558 |
- |
- |
1件: 299 |
169 |
Cayston 75 mg pulver und lösungsmittel zur herstellung einer lösung für einen vernebler |
Aztreonam |
D00240, D06558 |
- |
- |
1件: 299 |
170 |
Cefepime |
Cefepime |
D02376 |
- |
- |
2件: 60, 299 |
171 |
Ceftaroline |
Ceftaroline fosamil |
D08884 |
- |
- |
1件: 299 |
172 |
Ceftazidim |
Ceftazidime |
D00921, D07654 |
- |
- |
1件: 299 |
173 |
Ceftazidim fresenius kabi |
Ceftazidime |
D00921, D07654 |
- |
- |
1件: 299 |
174 |
Ceftazidim fresenius kabi 2000 mg poeder voor oplossing voor injectie of infusie |
Ceftazidime |
D00921, D07654 |
- |
- |
1件: 299 |
175 |
Ceftazidime |
Ceftazidime |
D00921, D07654 |
- |
- |
1件: 299 |
176 |
Ceftazidime and tobramycin |
Ceftazidime |
D00921, D07654 |
- |
- |
1件: 299 |
177 |
Ceftazidime pentahydrate |
Ceftazidime |
D00921, D07654 |
- |
- |
1件: 299 |
178 |
Ceftazidime/avibactam |
Ceftazidime |
D00921, D07654 |
- |
- |
1件: 299 |
179 |
Ceftolozane |
Ceftolozane |
D10097 |
- |
- |
1件: 299 |
180 |
Ceftolozane/tazobactam |
Ceftolozane |
D10097 |
- |
- |
1件: 299 |
181 |
Cf patients with a g551d mutation and treated with ivacaftor |
Ivacaftor |
D09916 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
182 |
Chf 6333 |
- |
- |
- |
- |
1件: 299 |
183 |
Chf6333 (part 1 - sad) |
- |
- |
- |
- |
1件: 299 |
184 |
Chf6333 (part 2 - mad) |
- |
- |
- |
- |
1件: 299 |
185 |
Chlorhexidine |
Chlorhexidine |
D00858, D01345, D03463, D07668 |
- |
- |
2件: 86, 299 |
186 |
Chlorhexidine gluconate |
Chlorhexidine |
D00858, D01345, D03463, D07668 |
- |
- |
1件: 299 |
187 |
Chlorhexidine gluconate oral rinse |
Chlorhexidine |
D00858, D01345, D03463, D07668 |
- |
- |
1件: 299 |
188 |
Chloride |
Chloride ion |
- |
- |
- |
17件: 6, 11, 13, 14, 34, 46, 51, 96, 97, 127, 168, 193, 227, 228, 288, 297, 299 |
189 |
Cholecalciferol |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
9件: 13, 19, 34, 46, 49, 96, 97, 298, 299 |
190 |
Cholecalciferol (vitamin d3) |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 299 |
191 |
Choline |
Choline |
D07690 |
- |
- |
4件: 65, 171, 193, 299 |
192 |
Choline chloride |
Choline |
D07690 |
- |
- |
1件: 299 |
193 |
Choline supplementation |
Choline |
D07690 |
- |
- |
1件: 299 |
194 |
Chronic antioxidant |
- |
- |
- |
- |
1件: 299 |
195 |
Cipro (ciprofloxacin, bayq3939) |
Ciprofloxacin |
D00186, D02216 |
- |
- |
1件: 299 |
196 |
Cipro inhale |
Ciprofloxacin |
D00186, D02216 |
- |
- |
1件: 299 |
197 |
Ciprofloxacin |
Ciprofloxacin |
D00186, D02216 |
- |
- |
5件: 2, 60, 96, 97, 299 |
198 |
Ciprofloxacin (cipro inhale, bayq3939) |
Ciprofloxacin |
D00186, D02216 |
- |
- |
1件: 299 |
199 |
Ciprofloxacin (cipro, bayq3939) |
Ciprofloxacin |
D00186, D02216 |
- |
- |
1件: 299 |
200 |
Ciprofloxacin (ciproxin) |
Ciprofloxacin |
D00186, D02216 |
- |
- |
1件: 299 |
201 |
Ciprofloxacin dispersion for inhalation |
Ciprofloxacin |
D00186, D02216 |
- |
- |
1件: 299 |
202 |
Ciprofloxacin dpi |
Ciprofloxacin |
D00186, D02216 |
- |
- |
1件: 299 |
203 |
Ciprofloxacin for inhalation |
Ciprofloxacin |
D00186, D02216 |
- |
- |
1件: 299 |
204 |
Ciprofloxacin hydrochloride |
Ciprofloxacin |
D00186, D02216 |
- |
- |
2件: 96, 299 |
205 |
Ciprofloxacin hydrochloride monohydrate |
Ciprofloxacin |
D00186, D02216 |
- |
- |
1件: 299 |
206 |
Ciproxin |
- |
- |
- |
- |
1件: 299 |
207 |
Ciproxin suspension |
- |
- |
- |
- |
1件: 299 |
208 |
Ciproxin*6cpr riv 500mg |
- |
- |
- |
- |
1件: 299 |
209 |
Clarithromycin |
Clarithromycin |
D00276 |
- |
- |
8件: 6, 63, 84, 96, 97, 222, 228, 299 |
210 |
Claritromycin |
- |
- |
- |
- |
1件: 299 |
211 |
Claritromycin 500mg film coated tablets |
- |
- |
- |
- |
1件: 299 |
212 |
Clavulanate |
Clavulanic acid |
D07711 |
- |
- |
1件: 299 |
213 |
Cloruro sodico 7% |
- |
- |
- |
- |
1件: 299 |
214 |
Cobamamide |
Cobamamide |
D00042 |
- |
- |
1件: 299 |
215 |
Colimycine inhalation |
- |
- |
- |
- |
1件: 299 |
216 |
Colimycine injectable |
- |
- |
- |
- |
1件: 299 |
217 |
Colistimethat-natrium |
- |
- |
- |
- |
1件: 299 |
218 |
Colistimethate |
Colistimethate |
D02049 |
- |
- |
1件: 299 |
219 |
Colistimethate 75 mg inhaled two times daily |
Colistimethate |
D02049 |
- |
- |
1件: 299 |
220 |
Colistimethate sodium |
Colistimethate |
D02049 |
- |
- |
1件: 299 |
221 |
Colistimethate sodium (a component) |
Colistimethate |
D02049 |
- |
- |
1件: 299 |
222 |
Colistimethate sodium (ban, usan), colistimethatum natricum, colistin sodium methanesulfonate |
Colistimethate |
D02049 |
- |
- |
1件: 299 |
223 |
Colistimethate sodium (promixin) |
Colistimethate |
D02049 |
- |
- |
1件: 299 |
224 |
Colistin |
Colistin |
D02138, D07746 |
- |
- |
1件: 299 |
225 |
Colistin cf |
Colistin |
D02138, D07746 |
- |
- |
1件: 299 |
226 |
Colistin forest - trockenstechampullen mit lösungsmittel |
Colistin |
D02138, D07746 |
- |
- |
1件: 299 |
227 |
Colistin mesilate sodium |
Colistin |
D02138, D07746 |
- |
- |
1件: 299 |
228 |
Colistineb |
- |
- |
- |
- |
1件: 299 |
229 |
Colistineb 2mui |
- |
- |
- |
- |
1件: 299 |
230 |
Colobreathe |
Colistimethate |
D02049 |
- |
- |
1件: 299 |
231 |
Colomycin |
- |
- |
- |
- |
1件: 299 |
232 |
Compound 1a |
- |
- |
- |
- |
2件: 246, 299 |
233 |
Continuous infusion cefepime |
Cefepime |
D02376 |
- |
- |
1件: 299 |
234 |
Continuous infusion ceftazidime |
Ceftazidime |
D00921, D07654 |
- |
- |
1件: 299 |
235 |
Continuous infusion meropenem |
Meropenem |
D02222, D08185 |
- |
- |
1件: 299 |
236 |
Continuous infusion piperacillin tazobactam |
Piperacillin |
D00466, D02251, D08380 |
- |
- |
1件: 299 |
237 |
Continuous infusion ticarcillin-clavulanate |
Ticarcillin |
D08593 |
- |
- |
1件: 299 |
238 |
Control group 0.9% isotonic saline |
- |
- |
- |
- |
1件: 299 |
239 |
Control multivitamin |
- |
- |
- |
- |
1件: 299 |
240 |
Cr002 |
Cr002 |
- |
- |
- |
1件: 299 |
241 |
Cr002 liquid api |
Cr002 |
- |
- |
- |
1件: 299 |
242 |
Crc3357, zk-355322, leukoton |
- |
- |
- |
- |
1件: 299 |
243 |
Creon |
Pancrelipase amylase |
- |
- |
- |
2件: 298, 299 |
244 |
Creon 10000 |
Pancrelipase amylase |
- |
- |
- |
2件: 298, 299 |
245 |
Creon 25000 |
Pancrelipase amylase |
- |
- |
- |
2件: 298, 299 |
246 |
Creon ir |
- |
- |
- |
- |
1件: 299 |
247 |
Creon n 25000 |
- |
- |
- |
- |
1件: 299 |
248 |
Creon® 25,000 |
- |
- |
- |
- |
1件: 299 |
249 |
Crestor |
Rosuvastatin |
D01915, D08492 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
3件: 49, 79, 299 |
250 |
Ctp-656, 100 mg (qd) |
- |
- |
- |
- |
1件: 299 |
251 |
Ctp-656, 150 mg (qd) |
- |
- |
- |
- |
1件: 299 |
252 |
Ctp-656, 20 mg (qd) |
- |
- |
- |
- |
1件: 299 |
253 |
Ctx-4430 |
- |
- |
- |
- |
1件: 299 |
254 |
Curcuma longa |
Turmeric |
- |
- |
- |
1件: 299 |
255 |
Curcuma longa extract |
Turmeric |
- |
- |
- |
1件: 299 |
256 |
Curcuma longa extract cpl formaat 00 23,2 x 8,5 mm 723 mg |
Turmeric |
- |
- |
- |
1件: 299 |
257 |
Curcumin |
Curcumin |
- |
- |
- |
10件: 13, 46, 49, 67, 74, 94, 96, 97, 139, 299 |
258 |
Cyc202 |
- |
- |
- |
- |
1件: 299 |
259 |
Cystagon |
Cysteamine |
D03634, D03635 |
- |
- |
3件: 8, 19, 299 |
260 |
Cystagon (cysteamine bitartrate) immediate-release capsules |
Cysteamine |
D03634, D03635 |
- |
- |
1件: 299 |
261 |
Cysteamine |
Cysteamine |
D03634, D03635 |
- |
- |
4件: 8, 19, 21, 299 |
262 |
Cysteamine bitartrate |
Cysteamine |
D03634, D03635 |
- |
- |
4件: 8, 19, 21, 299 |
263 |
Cysteamine bitartrate (cystagon) |
Cysteamine |
D03634, D03635 |
- |
- |
1件: 299 |
264 |
Cystic fibrosis ready to use supplemental food |
- |
- |
- |
- |
1件: 299 |
265 |
D-a-tocopheryl peg 1000 succinate |
Succinic acid |
- |
- |
- |
1件: 299 |
266 |
D-glucitol |
Sorbitol |
D00096 |
- |
- |
2件: 28, 299 |
267 |
D6-25-hydroxyvitamin d3 |
Calcifediol |
D00122 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 299 |
268 |
Dci 1020 |
- |
- |
- |
- |
1件: 299 |
269 |
Decolonization |
- |
- |
- |
- |
1件: 299 |
270 |
Denosumab |
Denosumab |
D03684 |
1件: TNFSF11 |
7件: Breast cancer, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis |
7件: 46, 50, 93, 95, 96, 274, 299 |
271 |
Denufosol |
Denufosol |
D03685 |
- |
- |
1件: 299 |
272 |
Denufosol tetrasodium (ins37217) |
Denufosol |
D03685 |
- |
- |
1件: 299 |
273 |
Denufosol tetrasodium (ins37217) inhalation solution |
Denufosol |
D03685 |
- |
- |
1件: 299 |
274 |
Denufosol tetrasodium inhalation solution |
Denufosol |
D03685 |
- |
- |
1件: 299 |
275 |
Depelestat |
- |
- |
- |
- |
1件: 299 |
276 |
Desoxyribonuclease |
Desoxyribonuclease |
- |
- |
- |
1件: 299 |
277 |
Detemir |
Insulin detemir |
D04539 |
1件: INSR |
20件: AMPK signaling pathway, Adherens junction, Aldosterone-regulated sodium reabsorption, FoxO signaling pathway, HIF-1 signaling pathway, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Non-alcoholic fatty liver disease (NAFLD), Ovarian steroidogenesis, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, cGMP-PKG signaling pathway, mTOR signaling pathway |
1件: 299 |
278 |
Detoxifying agents for antineoplastic treatment |
- |
- |
- |
- |
1件: 299 |
279 |
Deuterated ivacaftor |
Ivacaftor |
D09916 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
280 |
Dexamethasone |
Dexamethasone |
D00292, D00975, D01510, D01615, D01632, D01948, D02174, D02591, D02592 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
20件: 13, 16, 28, 35, 46, 53, 63, 65, 70, 74, 75, 81, 83, 84, 90, 96, 97, 222, 296, 299 |
281 |
Dexamethasone sodium phosphate 250 mg/10 ml solution |
Dexamethasone |
D00292, D00975, D01510, D01615, D01632, D01948, D02174, D02591, D02592 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 299 |
282 |
Diet |
- |
- |
- |
- |
2件: 240, 299 |
283 |
Digitoxin |
Digitoxin |
D00297 |
4件: ATP1A1, ATP1A2, ATP1A3, ATP1A4 |
18件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Bile secretion, Carbohydrate digestion and absorption, Cardiac muscle contraction, Endocrine and other factor-regulated calcium reabsorption, Gastric acid secretion, Insulin secretion, Mineral absorption, Pancreatic secretion, Protein digestion and absorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Thyroid hormone signaling pathway, Thyroid hormone synthesis, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 299 |
284 |
Docosahexaenoic acid |
Doconexent |
- |
- |
- |
7件: 6, 49, 90, 94, 240, 299, 301 |
285 |
Docosahexaenoic acid (dha) |
Doconexent |
- |
- |
- |
3件: 6, 94, 299 |
286 |
Docosahexaenoic acid administration: 50 mg/kg/day during 12 months |
Doconexent |
- |
- |
- |
1件: 299 |
287 |
Docosahexanoic acid supplement |
- |
- |
- |
- |
1件: 299 |
288 |
Doribax |
Doripenem |
D03895 |
- |
- |
1件: 299 |
289 |
Doripenem |
Doripenem |
D03895 |
- |
- |
1件: 299 |
290 |
Doripenem hydrate |
Doripenem |
D03895 |
- |
- |
1件: 299 |
291 |
Dornase alfa |
Dornase alfa |
D03896 |
- |
- |
2件: 53, 299 |
292 |
Dornase alfa (pulmozyme) |
Dornase alfa |
D03896 |
- |
- |
1件: 299 |
293 |
Dornase alfa [pulmozyme®] |
Dornase alfa |
D03896 |
- |
- |
1件: 299 |
294 |
Dornase alpha |
Dornase alfa |
D03896 |
- |
- |
1件: 299 |
295 |
Doxycycline |
Doxycycline |
D00307, D02129, D03903, D03904, D07876 |
- |
- |
15件: 13, 23, 28, 46, 84, 85, 89, 96, 97, 158, 162, 167, 227, 280, 299 |
296 |
Dp mannitol |
Mannitol |
D00062 |
- |
- |
1件: 299 |
297 |
Dry powder tobramycin |
Tobramycin |
D00063, D02542 |
- |
- |
1件: 299 |
298 |
Dtpa |
Pentetic acid |
D05422 |
- |
- |
3件: 13, 28, 299 |
299 |
Duramycin |
Lancovutide |
- |
- |
- |
1件: 299 |
300 |
Duramycin, 2622u90 |
Lancovutide |
- |
- |
- |
1件: 299 |
301 |
Ebselen |
Ebselen |
- |
- |
- |
1件: 299 |
302 |
Ecgc |
- |
- |
- |
- |
1件: 299 |
303 |
Egcg |
Epigallocatechin gallate |
- |
- |
- |
8件: 6, 13, 17, 28, 85, 113, 206, 299 |
304 |
Egcg + tocotrienol |
Tocotrienol |
- |
- |
- |
1件: 299 |
305 |
Elexacaftor |
Elexacaftor |
D11507 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
306 |
Elexacaftor-tezacaftor-ivacaftor exposure |
Elexacaftor |
D11507 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
307 |
Elx-02 |
- |
- |
- |
- |
2件: 19, 299 |
308 |
Elx/tez/iva |
- |
- |
- |
- |
1件: 299 |
309 |
Emea/h/c/000125 |
- |
- |
- |
- |
1件: 299 |
310 |
Engineerd protein inhibitor of human neutrophil elastase |
- |
- |
- |
- |
1件: 299 |
311 |
Engineered protein inhibitor of human neutrophil elastase |
- |
- |
- |
- |
1件: 299 |
312 |
Ensure high protein |
- |
- |
- |
- |
1件: 299 |
313 |
Ensure plus |
- |
- |
- |
- |
1件: 299 |
314 |
Epi-hne4 dx-890 |
- |
- |
- |
- |
1件: 299 |
315 |
Ergocalciferol |
Ergocalciferol |
D00187 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
5件: 46, 84, 96, 97, 299 |
316 |
Ergocalciferol (vitamin d2) |
Ergocalciferol |
D00187 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 299 |
317 |
Esomeprazole |
Esomeprazole |
D01984, D04056, D07917, D09339 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
6件: 6, 46, 86, 98, 298, 299 |
318 |
Essential amino acid intake + leucine vs total aa supplement |
L-leucine |
D00030 |
- |
- |
1件: 299 |
319 |
Estradiol |
Estradiol |
D00105, D01413, D01617, D01953, D04061, D04063, D04064, D04065 |
2件: ESR1, ESR2 |
9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
5件: 13, 46, 49, 226, 299 |
320 |
Estradiol 2 mg |
Estradiol |
D00105, D01413, D01617, D01953, D04061, D04063, D04064, D04065 |
2件: ESR1, ESR2 |
9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
1件: 299 |
321 |
Ethambutol |
Ethambutol |
D00878, D07925 |
- |
- |
2件: 84, 299 |
322 |
Ethinyl estradiol |
Estradiol |
D00105, D01413, D01617, D01953, D04061, D04063, D04064, D04065 |
2件: ESR1, ESR2 |
9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
3件: 46, 49, 299 |
323 |
Eu orphan designation number eu/3/02/120 |
- |
- |
- |
- |
1件: 299 |
324 |
Eur-1008 |
- |
- |
- |
- |
1件: 299 |
325 |
Eur-1008 (apt-1008) |
- |
- |
- |
- |
1件: 299 |
326 |
Ez-2053 |
- |
- |
- |
- |
2件: 85, 299 |
327 |
Ez-2053 5mg/kg |
- |
- |
- |
- |
2件: 85, 299 |
328 |
Fdl169 |
- |
- |
- |
- |
1件: 299 |
329 |
Fdl176 |
- |
- |
- |
- |
1件: 299 |
330 |
Fdl176 & fdl169 coadministration |
- |
- |
- |
- |
1件: 299 |
331 |
Fenretinide |
Fenretinide |
D04162 |
2件: RARA, RARB |
8件: Acute myeloid leukemia, Estrogen signaling pathway, Gastric cancer, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer |
1件: 299 |
332 |
Ferric carboxymaltose |
Ferric carboxymaltose |
D08920 |
- |
- |
4件: 86, 96, 97, 299 |
333 |
Ferrous sulfate 325mg |
Sulfate ion |
- |
- |
- |
1件: 299 |
334 |
Finely ground flaxseed powder |
- |
- |
- |
- |
1件: 299 |
335 |
Fish oil |
Fish oil |
- |
- |
- |
7件: 13, 46, 49, 66, 96, 260, 299 |
336 |
Flucloxacillin |
Flucloxacillin |
D01249, D04196, D07965 |
- |
- |
1件: 299 |
337 |
Flucloxacillin 250mg/5ml sugar-free powder for oral solution |
Flucloxacillin |
D01249, D04196, D07965 |
- |
- |
1件: 299 |
338 |
Flucloxacillin sodium |
Flucloxacillin |
D01249, D04196, D07965 |
- |
- |
1件: 299 |
339 |
Flucloxicillin |
- |
- |
- |
- |
1件: 299 |
340 |
Flumist® |
- |
- |
- |
- |
1件: 299 |
341 |
Fluticasone |
Fluticasone |
D07981 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
4件: 98, 228, 299, 306 |
342 |
Formoterol |
Formoterol |
D01373, D05277, D07990 |
1件: ADRB2 |
8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
3件: 228, 299, 306 |
343 |
Fortum |
- |
- |
- |
- |
1件: 299 |
344 |
Fti, azli |
- |
- |
- |
- |
1件: 299 |
345 |
G1117337 |
- |
- |
- |
- |
1件: 299 |
346 |
G957389 |
- |
- |
- |
- |
1件: 299 |
347 |
Gallium nitrate |
Gallium nitrate |
D00940 |
- |
- |
1件: 299 |
348 |
Garlic |
Garlic |
- |
- |
- |
1件: 299 |
349 |
Genistein |
Genistein |
D11680 |
- |
- |
2件: 19, 299 |
350 |
Genistein (unconjugated isoflavones 100) |
Genistein |
D11680 |
- |
- |
1件: 299 |
351 |
Genisteine plus 150 mg cpl formaat 1 18,7 x 6,4 mm 438 mg |
- |
- |
- |
- |
1件: 299 |
352 |
Gentamicin |
Gentamicin |
D01063, D08013 |
- |
- |
3件: 36, 113, 299 |
353 |
Gernebcin 80 mg |
- |
- |
- |
- |
1件: 299 |
354 |
Ghrelin |
Lenomorelin |
- |
- |
- |
3件: 6, 78, 299 |
355 |
Giving dha-rich supplement |
- |
- |
- |
- |
1件: 299 |
356 |
Glargine |
Insulin glargine |
D03250 |
1件: INSR |
20件: AMPK signaling pathway, Adherens junction, Aldosterone-regulated sodium reabsorption, FoxO signaling pathway, HIF-1 signaling pathway, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Non-alcoholic fatty liver disease (NAFLD), Ovarian steroidogenesis, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, cGMP-PKG signaling pathway, mTOR signaling pathway |
1件: 299 |
357 |
Glargine insulin |
Insulin glargine |
D03250 |
1件: INSR |
20件: AMPK signaling pathway, Adherens junction, Aldosterone-regulated sodium reabsorption, FoxO signaling pathway, HIF-1 signaling pathway, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Non-alcoholic fatty liver disease (NAFLD), Ovarian steroidogenesis, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, cGMP-PKG signaling pathway, mTOR signaling pathway |
1件: 299 |
358 |
Glp-1 |
- |
- |
- |
- |
1件: 299 |
359 |
Glpg1837 |
- |
- |
- |
- |
1件: 299 |
360 |
Glpg2222 |
- |
- |
- |
- |
1件: 299 |
361 |
Glpg2222 150 mg q.d. |
- |
- |
- |
- |
1件: 299 |
362 |
Glpg2222 300 mg q.d. |
- |
- |
- |
- |
1件: 299 |
363 |
Glpg2222 dose 1 for cohort a |
- |
- |
- |
- |
1件: 299 |
364 |
Glpg2222 dose 1 for cohort b |
- |
- |
- |
- |
1件: 299 |
365 |
Glpg2222 dose 2 for cohort a |
- |
- |
- |
- |
1件: 299 |
366 |
Glpg2222 dose 2 for cohort b |
- |
- |
- |
- |
1件: 299 |
367 |
Glpg2451 dose regimen a |
- |
- |
- |
- |
1件: 299 |
368 |
Glpg2451 dose regimen b |
- |
- |
- |
- |
1件: 299 |
369 |
Glpg2737 |
- |
- |
- |
- |
1件: 299 |
370 |
Glpg2737 single dose |
- |
- |
- |
- |
1件: 299 |
371 |
Glpg3067 single dose |
- |
- |
- |
- |
1件: 299 |
372 |
Glucose |
D-glucose |
D00009 |
- |
- |
3件: 6, 13, 299 |
373 |
Glutamine |
L-glutamine |
D00015 |
- |
- |
6件: 87, 96, 97, 113, 245, 299 |
374 |
Glutathione |
Glutathione |
D00014, D00031 |
- |
- |
2件: 6, 299 |
375 |
Glutathione sodium |
Glutathione |
D00014, D00031 |
- |
- |
1件: 299 |
376 |
Glycine |
Glycine |
D00011 |
- |
- |
4件: 35, 86, 226, 299 |
377 |
Glycine buffer |
Glycine |
D00011 |
- |
- |
1件: 299 |
378 |
Growth hormone |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
11件: 2, 13, 19, 46, 78, 96, 191, 193, 195, 265, 299 |
379 |
Gs-5737 |
- |
- |
- |
- |
1件: 299 |
380 |
Gs-9411 |
- |
- |
- |
- |
1件: 299 |
381 |
Gsh (glutathione) |
Glutathione |
D00014, D00031 |
- |
- |
1件: 299 |
382 |
Helium |
Helium |
D04420 |
- |
- |
3件: 228, 299, 330 |
383 |
Helium-3 |
Helium |
D04420 |
- |
- |
2件: 228, 299 |
384 |
Heparin |
Heparin |
D07510 |
1件: SERPINC1 |
1件: Complement and coagulation cascades |
11件: 60, 70, 79, 84, 107, 224, 226, 280, 299, 316, 317 |
385 |
Heparin 25mg inhalation powder, hard capsule |
Heparin |
D07510 |
1件: SERPINC1 |
1件: Complement and coagulation cascades |
1件: 299 |
386 |
Heparin sodium |
Heparin |
D07510 |
1件: SERPINC1 |
1件: Complement and coagulation cascades |
2件: 280, 299 |
387 |
High dose of budesonide |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 299 |
388 |
High-dose vitamin d3 |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 299 |
389 |
Hmscs |
- |
- |
- |
- |
1件: 299 |
390 |
Hp 129xe |
- |
- |
- |
- |
1件: 299 |
391 |
Hp 3he |
- |
- |
- |
- |
1件: 299 |
392 |
Human recombinant growth hormone |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
2件: 13, 299 |
393 |
Hyaluronan |
Hyaluronic acid |
D08043 |
- |
- |
1件: 299 |
394 |
Hydrocortisone |
Hydrocortisone |
D00088 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
8件: 6, 53, 75, 78, 81, 83, 97, 299 |
395 |
Hydroxychloroquine |
Hydroxychloroquine |
D08050 |
- |
- |
18件: 13, 41, 46, 48, 49, 53, 56, 66, 84, 89, 90, 96, 222, 234, 254, 271, 298, 299 |
396 |
Hyperglycemic clamp |
- |
- |
- |
- |
1件: 299 |
397 |
Hyperglycemic clamp with concurrent gip infusion |
- |
- |
- |
- |
1件: 299 |
398 |
Hyperglycemic clamp with concurrent glp-1 infusion |
- |
- |
- |
- |
1件: 299 |
399 |
Hyperpolarized helium-3 |
Helium |
D04420 |
- |
- |
1件: 299 |
400 |
Hyperpolarized helium-3 mri of the chest |
Helium |
D04420 |
- |
- |
1件: 299 |
401 |
Hyperpolarized xenon |
Xenon |
D01901, D06339 |
- |
- |
1件: 299 |
402 |
Hyperpolarized xenon gas |
Xenon |
D01901, D06339 |
- |
- |
1件: 299 |
403 |
Hypertonic bicarbonate |
- |
- |
- |
- |
1件: 299 |
404 |
Hypertonic saline |
- |
- |
- |
- |
1件: 299 |
405 |
Hypertonic saline (7 %) and isotonic saline (0.9%) |
- |
- |
- |
- |
1件: 299 |
406 |
Hypertonic saline (7%) |
- |
- |
- |
- |
1件: 299 |
407 |
Hypertonic saline 6% - |
- |
- |
- |
- |
1件: 299 |
408 |
Hypertonic saline 7% |
- |
- |
- |
- |
1件: 299 |
409 |
Hypertonic saline solution |
Sodium chloride |
D02056 |
- |
- |
1件: 299 |
410 |
Ibuprofen |
Ibuprofen |
D00126, D01122, D04490, D06606 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
6件: 13, 46, 65, 113, 271, 299 |
411 |
Ics+laba |
- |
- |
- |
- |
1件: 299 |
412 |
Idpm |
- |
- |
- |
- |
1件: 299 |
413 |
Idpm: inhaled dry powder mannitol |
Mannitol |
D00062 |
- |
- |
1件: 299 |
414 |
Ige025 |
- |
- |
- |
- |
1件: 299 |
415 |
Impact |
Topramezone |
- |
- |
- |
7件: 6, 13, 46, 50, 96, 97, 299 |
416 |
Impact-nutridrink |
Topramezone |
- |
- |
- |
1件: 299 |
417 |
Increlex*sc 1fl 4ml 10mg/ml |
Mecasermin |
D03297, D04870 |
2件: GHR, IGF1R |
33件: AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway |
1件: 299 |
418 |
Indium |
Indium |
- |
- |
- |
3件: 28, 84, 299 |
419 |
Indium-dtpa |
Indium |
- |
- |
- |
1件: 299 |
420 |
Indusil*os gtt fl 30mg+fl 15ml |
- |
- |
- |
- |
1件: 299 |
421 |
Inhaled 7% hypertonic saline (hs) |
- |
- |
- |
- |
1件: 299 |
422 |
Inhaled ar-501 |
- |
- |
- |
- |
1件: 299 |
423 |
Inhaled dry powder mannitol |
Mannitol |
D00062 |
- |
- |
1件: 299 |
424 |
Inhaled hypertonic saline (7%) |
- |
- |
- |
- |
1件: 299 |
425 |
Inhaled mannitol |
Mannitol |
D00062 |
- |
- |
1件: 299 |
426 |
Inhaled reduced glutathione |
Glutathione |
D00014, D00031 |
- |
- |
1件: 299 |
427 |
Inhaled snsp113 |
- |
- |
- |
- |
1件: 299 |
428 |
Inhaled sodium pyruvate |
Pyruvic acid |
- |
- |
- |
1件: 299 |
429 |
Inhaled tobramycin |
Tobramycin |
D00063, D02542 |
- |
- |
1件: 299 |
430 |
Inhaled vancomycin |
Vancomycin |
D00212, D00926 |
- |
- |
1件: 299 |
431 |
Inomax 400ppm mol/mol inhalation gas |
Nitric oxide |
D00074 |
- |
- |
2件: 85, 299 |
432 |
Ins1007 10 mg oral tablet |
- |
- |
- |
- |
1件: 299 |
433 |
Ins1007 25 mg oral tablet |
- |
- |
- |
- |
1件: 299 |
434 |
Insulin |
- |
- |
- |
- |
5件: 13, 46, 75, 78, 299 |
435 |
Insulin asparte |
- |
- |
- |
- |
1件: 299 |
436 |
Insulin detemir |
Insulin detemir |
D04539 |
1件: INSR |
20件: AMPK signaling pathway, Adherens junction, Aldosterone-regulated sodium reabsorption, FoxO signaling pathway, HIF-1 signaling pathway, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Non-alcoholic fatty liver disease (NAFLD), Ovarian steroidogenesis, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, cGMP-PKG signaling pathway, mTOR signaling pathway |
1件: 299 |
437 |
Insulin detemir [rdna origin] injection |
Insulin detemir |
D04539 |
1件: INSR |
20件: AMPK signaling pathway, Adherens junction, Aldosterone-regulated sodium reabsorption, FoxO signaling pathway, HIF-1 signaling pathway, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Non-alcoholic fatty liver disease (NAFLD), Ovarian steroidogenesis, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, cGMP-PKG signaling pathway, mTOR signaling pathway |
1件: 299 |
438 |
Insulin glargine |
Insulin glargine |
D03250 |
1件: INSR |
20件: AMPK signaling pathway, Adherens junction, Aldosterone-regulated sodium reabsorption, FoxO signaling pathway, HIF-1 signaling pathway, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Non-alcoholic fatty liver disease (NAFLD), Ovarian steroidogenesis, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, cGMP-PKG signaling pathway, mTOR signaling pathway |
1件: 299 |
439 |
Insuline humaine recombinante |
- |
- |
- |
- |
1件: 299 |
440 |
Interferon gamma-1b |
- |
- |
- |
- |
7件: 65, 85, 90, 228, 299, 301, 326 |
441 |
Intermittent, short infusion cefepime |
Cefepime |
D02376 |
- |
- |
1件: 299 |
442 |
Intermittent, short infusion ceftazidime |
Ceftazidime |
D00921, D07654 |
- |
- |
1件: 299 |
443 |
Intermittent, short infusion meropenem |
Meropenem |
D02222, D08185 |
- |
- |
1件: 299 |
444 |
Intermittent, short infusion piperacillin tazobactam |
Piperacillin |
D00466, D02251, D08380 |
- |
- |
1件: 299 |
445 |
Intermittent, short infusion ticarcillin-clavulanate |
Ticarcillin |
D08593 |
- |
- |
1件: 299 |
446 |
Inulin |
Inulin |
D00171 |
- |
- |
2件: 96, 299 |
447 |
Ionis-enacrx |
- |
- |
- |
- |
1件: 299 |
448 |
Isotonic saline |
- |
- |
- |
- |
1件: 299 |
449 |
Itraconazole |
Itraconazole |
D00350 |
- |
- |
4件: 3, 65, 227, 299 |
450 |
Itraconazole/voriconazole |
Itraconazole, Voriconazole |
D00350, D00578 |
- |
- |
1件: 299 |
451 |
Iv amikacin |
Amikacin |
D00865, D02543 |
- |
- |
1件: 299 |
452 |
Iv ceftazidime |
Ceftazidime |
D00921, D07654 |
- |
- |
1件: 299 |
453 |
Iv meropenem |
Meropenem |
D02222, D08185 |
- |
- |
1件: 299 |
454 |
Iv piperacillin-tazobactam |
Piperacillin |
D00466, D02251, D08380 |
- |
- |
1件: 299 |
455 |
Iv ticarcillin-clavulanate |
Ticarcillin |
D08593 |
- |
- |
1件: 299 |
456 |
Iv tobramycin |
Tobramycin |
D00063, D02542 |
- |
- |
1件: 299 |
457 |
Iv vancomycin hydrochloride |
Vancomycin |
D00212, D00926 |
- |
- |
1件: 299 |
458 |
Ivacaftor |
Ivacaftor |
D09916 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
459 |
Ivacaftor 125mg tablet |
Ivacaftor |
D09916 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
460 |
Ivacaftor 150 mg or 250 mg |
Ivacaftor |
D09916 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
461 |
Ivacaftor 25 mg/75 mg |
Ivacaftor |
D09916 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
462 |
Ivacaftor 75 mg/150 mg |
Ivacaftor |
D09916 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
463 |
Ivacaftor exposed |
Ivacaftor |
D09916 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
464 |
Ivacaftor+lumacaftor |
Lumacaftor |
D10134 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
465 |
Ivacaftor/kalydeco |
Ivacaftor |
D09916 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
466 |
J01gb01 |
- |
- |
- |
- |
1件: 299 |
467 |
Jbt-101 |
- |
- |
- |
- |
4件: 49, 50, 51, 299 |
468 |
Jbt-101 (lenabasum) |
- |
- |
- |
- |
1件: 299 |
469 |
Kalydeco |
Ivacaftor |
D09916 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
470 |
Kalydeco 150 mg film-coated tablets |
Ivacaftor |
D09916 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
471 |
Kalydeco 150mg |
Ivacaftor |
D09916 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
472 |
Kalydeco, 150 mg tablet (bid |
- |
- |
- |
- |
1件: 299 |
473 |
Kb001 |
Kb001 |
- |
- |
- |
1件: 299 |
474 |
Kb001-a |
Kb001 |
- |
- |
- |
1件: 299 |
475 |
Kineret |
Anakinra |
D02934 |
2件: IL1R1, IL1R2 |
15件: Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer |
5件: 41, 49, 65, 266, 299 |
476 |
Kreon 25 000 |
- |
- |
- |
- |
1件: 299 |
477 |
Kreon 25000 |
- |
- |
- |
- |
2件: 298, 299 |
478 |
L-alanine |
L-alanine |
D00012 |
- |
- |
1件: 299 |
479 |
L-arginine |
L-arginine |
D02982 |
- |
- |
4件: 67, 78, 113, 299 |
480 |
L-lysine |
L-lysine |
D02304 |
- |
- |
1件: 299 |
481 |
L-lysine-n-acetylcysteinate |
L-lysine |
D02304 |
- |
- |
1件: 299 |
482 |
Lactic acid |
Lactic acid |
D00111 |
- |
- |
2件: 265, 299 |
483 |
Lactic acid producing organisms |
Lactic acid |
D00111 |
- |
- |
1件: 299 |
484 |
Lactizole nebulization |
- |
- |
- |
- |
1件: 299 |
485 |
Lactobacillus reuteri |
Lactobacillus reuteri |
- |
- |
- |
2件: 97, 299 |
486 |
Lactobacillus rhamnosus |
- |
- |
- |
- |
1件: 299 |
487 |
Lactobacillus rhamnosus gg |
- |
- |
- |
- |
1件: 299 |
488 |
Lansoprazole |
Lansoprazole |
D00355 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
6件: 63, 71, 98, 166, 222, 299 |
489 |
Lantus 100 units/ml solution for injection in a cartridge |
- |
- |
- |
- |
1件: 299 |
490 |
Lantus*sc 5car3ml100ui/ml |
Insulin glargine |
D03250 |
1件: INSR |
20件: AMPK signaling pathway, Adherens junction, Aldosterone-regulated sodium reabsorption, FoxO signaling pathway, HIF-1 signaling pathway, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Non-alcoholic fatty liver disease (NAFLD), Ovarian steroidogenesis, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, cGMP-PKG signaling pathway, mTOR signaling pathway |
1件: 299 |
491 |
Lantus® 100 units/ml solution for injection in a vial. lantus® 100 units/ml solution for injection in a cartridge. lantus® 100 units/ml solution for injection in a pre-filled pen |
- |
- |
- |
- |
1件: 299 |
492 |
Lau-7b |
- |
- |
- |
- |
1件: 299 |
493 |
Lenabasum |
- |
- |
- |
- |
3件: 50, 51, 299 |
494 |
Lenabasum 20 mg |
- |
- |
- |
- |
3件: 50, 51, 299 |
495 |
Lenabasum 5 mg |
- |
- |
- |
- |
3件: 50, 51, 299 |
496 |
Leucine |
L-leucine |
D00030 |
- |
- |
7件: 5, 6, 7, 127, 283, 284, 299 |
497 |
Levemir 100 u/ml solution for injection in a cartridge, levemir 100 u/ml solution for injection in a pre-filled pen |
- |
- |
- |
- |
1件: 299 |
498 |
Levemir flexpen |
- |
- |
- |
- |
1件: 299 |
499 |
Levemir insulin |
- |
- |
- |
- |
1件: 299 |
500 |
Levemir penfill |
- |
- |
- |
- |
1件: 299 |
501 |
Levofloxacin |
Levofloxacin |
D00588, D08120 |
- |
- |
2件: 84, 299 |
502 |
Linezolid |
Linezolid |
D00947 |
- |
- |
1件: 299 |
503 |
Lipase clec |
- |
- |
- |
- |
1件: 299 |
504 |
Liposomal amikacin (arikace™) |
Amikacin |
D00865, D02543 |
- |
- |
1件: 299 |
505 |
Liposomal amikacin for inhalation |
Amikacin |
D00865, D02543 |
- |
- |
1件: 299 |
506 |
Liposomal amikacin for inhalation (arikayce™) using the pari investigational eflow® nebulizer. |
Amikacin |
D00865, D02543 |
- |
- |
1件: 299 |
507 |
Liposomal amphotericin b (ambisome®) |
Amphotericin b |
D00203 |
- |
- |
1件: 299 |
508 |
Liprotamase |
- |
- |
- |
- |
2件: 298, 299 |
509 |
Liprotamase powder for oral solution |
- |
- |
- |
- |
1件: 299 |
510 |
Loestrin (norethindrone acetate and ethinyl estradiol) |
Estradiol |
D00105, D01413, D01617, D01953, D04061, D04063, D04064, D04065 |
2件: ESR1, ESR2 |
9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
1件: 299 |
511 |
Losartan |
Losartan |
D00357, D08146 |
1件: AGTR1 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
18件: 13, 17, 19, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 |
512 |
Lu 70274 |
- |
- |
- |
- |
1件: 299 |
513 |
Lubiprostone |
Lubiprostone |
D04790 |
1件: CLCN2 |
1件: Mineral absorption |
4件: 6, 13, 290, 299 |
514 |
Lucinactant |
Lucinactant |
D04792 |
- |
- |
1件: 299 |
515 |
Lucinactant first |
Lucinactant |
D04792 |
- |
- |
1件: 299 |
516 |
Lum/iva |
- |
- |
- |
- |
1件: 299 |
517 |
Lum/iva fixed-dose combination |
- |
- |
- |
- |
1件: 299 |
518 |
Lumacaftor |
Lumacaftor |
D10134 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
519 |
Lumacaftor / ivacaftor |
Lumacaftor |
D10134 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
520 |
Lumacaftor plus ivacaftor |
Lumacaftor |
D10134 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
521 |
Lumacaftor plus ivacaftor combination |
Lumacaftor |
D10134 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
522 |
Lumacaftor-ivacaftor |
Lumacaftor |
D10134 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
523 |
Lumacaftor-ivacaftor treatment |
Lumacaftor |
D10134 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
524 |
Lumacaftor/ ivacaftor |
Lumacaftor |
D10134 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
525 |
Lumacaftor/ivacaftor |
Lumacaftor |
D10134 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
526 |
Lumacaftor/ivacaftor 100mg/125mg tablets |
Lumacaftor |
D10134 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
527 |
Lumacaftor/ivacaftor 200mg/125mg tablets |
Lumacaftor |
D10134 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
528 |
Lumacaftor/ivacaftor 200mg/83mg tablet |
Lumacaftor |
D10134 |
1件: CFTR |
8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
1件: 299 |
529 |
Lym-x-sorb powder |
- |
- |
- |
- |
1件: 299 |
530 |
Lysine |
L-lysine |
D02304 |
- |
- |
4件: 13, 97, 228, 299 |
531 |
Lysomucil 10 % |
- |
- |
- |
- |
1件: 299 |
532 |
Mag-dha |
- |
- |
- |
- |
1件: 299 |
533 |
Mannitol |
Mannitol |
D00062 |
- |
- |
3件: 6, 96, 299 |
534 |
Mannitol + pulmozyme |
Mannitol |
D00062 |
- |
- |
1件: 299 |
535 |
Mannitol inhalation powder |
Mannitol |
D00062 |
- |
- |
1件: 299 |
536 |
Matched isoglycemic clamp |
- |
- |
- |
- |
1件: 299 |
537 |
Mecasermin |
Mecasermin |
D03297, D04870 |
2件: GHR, IGF1R |
33件: AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway |
5件: 78, 96, 168, 265, 299 |
538 |
Medical grade oxygen |
Oxygen |
D00003 |
- |
- |
1件: 299 |
539 |
Menadiol diphosphate |
Menadiol diphosphate |
D08176 |
- |
- |
1件: 299 |
540 |
Menadiol sodium diphosphate |
Kappadione |
D04908 |
- |
- |
1件: 299 |
541 |
Meropenem |
Meropenem |
D02222, D08185 |
- |
- |
1件: 299 |
542 |
Meropenem fresenius kabi |
Meropenem |
D02222, D08185 |
- |
- |
1件: 299 |
543 |
Meropenem fresenius kabi 1 g poeder voor oplossing voor injectie of infusie |
Meropenem |
D02222, D08185 |
- |
- |
1件: 299 |
544 |
Meropenem infusion |
Meropenem |
D02222, D08185 |
- |
- |
1件: 299 |
545 |
Meropenem trihydrate |
Meropenem |
D02222, D08185 |
- |
- |
1件: 299 |
546 |
Mesenchymal stem cells |
- |
- |
- |
- |
11件: 2, 6, 13, 20, 49, 51, 60, 96, 222, 274, 299 |
547 |
Metformine |
Metformin |
D00944, D04966 |
2件: PRKAA1, PRKAA2 |
19件: AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy (HCM), Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease (NAFLD), Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway |
2件: 81, 299 |
548 |
Metformine hcl 500 pch |
Metformin |
D00944, D04966 |
2件: PRKAA1, PRKAA2 |
19件: AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy (HCM), Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease (NAFLD), Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway |
1件: 299 |
549 |
Miglustat |
Miglustat |
D05032 |
1件: UGCG |
2件: Metabolic pathways, Sphingolipid metabolism |
3件: 19, 256, 299 |
550 |
Minocycline |
Minocycline |
D00850, D05045 |
- |
- |
13件: 2, 6, 8, 13, 46, 85, 90, 94, 162, 201, 206, 280, 299 |
551 |
Minocycline hydrochloride |
Minocycline |
D00850, D05045 |
- |
- |
4件: 13, 201, 206, 299 |
552 |
Mirnas isolation from blood samples of patients and control |
- |
- |
- |
- |
1件: 299 |
553 |
Modified lipid formulation |
- |
- |
- |
- |
1件: 299 |
554 |
Modified oral glucose tolerance test (50g 4-hours) |
- |
- |
- |
- |
1件: 299 |
555 |
Molgramostim |
Molgramostim |
D05066 |
1件: CSF2RA |
4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer |
2件: 229, 299 |
556 |
Molgramostim nebulizer solution |
Molgramostim |
D05066 |
1件: CSF2RA |
4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer |
1件: 299 |
557 |
Moli1901 |
- |
- |
- |
- |
1件: 299 |
558 |
Moli1901 (2622u90, duramycin) |
Lancovutide |
- |
- |
- |
1件: 299 |
559 |
Moxifloxacin |
Moxifloxacin |
D00874, D08237 |
- |
- |
8件: 2, 6, 46, 49, 85, 86, 240, 299 |
560 |
Moxifloxacin hydrochloride |
Moxifloxacin |
D00874, D08237 |
- |
- |
1件: 299 |
561 |
Mp-376 |
- |
- |
- |
- |
1件: 299 |
562 |
Mp-376 (levofloxacin solution for inhalation) |
Levofloxacin |
D00588, D08120 |
- |
- |
1件: 299 |
563 |
Mri with pfp |
- |
- |
- |
- |
1件: 299 |
564 |
Mrt5005 |
- |
- |
- |
- |
1件: 299 |
565 |
Ms1819 |
Ms1819 |
- |
- |
- |
2件: 298, 299 |
566 |
Ms1819-sd |
Ms1819 |
- |
- |
- |
2件: 298, 299 |
567 |
Msi-1995 |
- |
- |
- |
- |
1件: 299 |
568 |
Mucoid exopolysaccharide p. aeruginosa immune globulin iv |
- |
- |
- |
- |
1件: 299 |
569 |
Mucolysin |
- |
- |
- |
- |
1件: 299 |
570 |
Mucomyst |
Acetylcysteine |
D00221 |
- |
- |
1件: 299 |
571 |
Mupirocin |
Mupirocin |
D01076, D02195 |
- |
- |
2件: 227, 299 |
572 |
Mupirocin intranasal creme |
Mupirocin |
D01076, D02195 |
- |
- |
1件: 299 |
573 |
N-(5-hydroxy-2,4-bis(trimethylsilyl)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide |
- |
- |
- |
- |
1件: 299 |
574 |
N-(trans-3-(5-((r)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)cyclobutyl)-3-phenylisoxazole-5-carboxamide |
- |
- |
- |
- |
1件: 299 |
575 |
N-acetylcystein |
- |
- |
- |
- |
1件: 299 |
576 |
N-acetylcysteine |
Acetylcysteine |
D00221 |
- |
- |
10件: 6, 13, 19, 20, 49, 58, 85, 111, 164, 299 |
577 |
N-acetylcysteine (nac) |
Acetylcysteine |
D00221 |
- |
- |
2件: 51, 299 |
578 |
N6022 |
N6022 |
- |
- |
- |
1件: 299 |
579 |
N91115 |
- |
- |
- |
- |
1件: 299 |
580 |
Nacystelyn® |
- |
- |
- |
- |
1件: 299 |
581 |
Nasal aztreonam |
Aztreonam |
D00240, D06558 |
- |
- |
1件: 299 |
582 |
Neb/01-07 |
- |
- |
- |
- |
1件: 299 |
583 |
Nebcin |
- |
- |
- |
- |
1件: 299 |
584 |
Nebcinal |
- |
- |
- |
- |
1件: 299 |
585 |
Nebcinal tobi |
- |
- |
- |
- |
1件: 299 |
586 |
Nebcine |
- |
- |
- |
- |
1件: 299 |
587 |
Nebulization of amikacin during niv (rr: 15 cycles/minute) |
Amikacin |
D00865, D02543 |
- |
- |
1件: 299 |
588 |
Nebulization of amikacin during niv (rr: 25 cycles/minute) |
Amikacin |
D00865, D02543 |
- |
- |
1件: 299 |
589 |
Nexium |
Esomeprazole |
D01984, D04056, D07917, D09339 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
1件: 299 |
590 |
Nexium 20 |
Esomeprazole |
D01984, D04056, D07917, D09339 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
1件: 299 |
591 |
Nitrate |
Nitrate |
D02313 |
- |
- |
3件: 58, 113, 299 |
592 |
Nitric oxide |
Nitric oxide |
D00074 |
- |
- |
7件: 46, 85, 86, 98, 251, 294, 299 |
593 |
Nitric oxide 160 ppm |
Nitric oxide |
D00074 |
- |
- |
1件: 299 |
594 |
Nitric oxide for inhalation |
Nitric oxide |
D00074 |
- |
- |
2件: 86, 299 |
595 |
Nitrite |
Nitrite |
- |
- |
- |
2件: 86, 299 |
596 |
Nitrogen |
Nitrogen |
D00083 |
- |
- |
5件: 5, 6, 17, 211, 299 |
597 |
None |
- |
- |
- |
- |
8件: 46, 78, 84, 96, 160, 161, 171, 299 |
598 |
None assigned |
- |
- |
- |
- |
2件: 231, 299 |
599 |
Norethindrone |
Norethisterone |
D00182, D00953 |
1件: PGR |
4件: Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
4件: 13, 46, 49, 299 |
600 |
Norgestimate |
Norgestimate |
D05209 |
1件: PGR |
4件: Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
1件: 299 |
601 |
Normal saline |
- |
- |
- |
- |
14件: 6, 17, 22, 36, 46, 49, 60, 94, 96, 211, 226, 276, 296, 299 |
602 |
Normal saline iv, salt tablets |
- |
- |
- |
- |
1件: 299 |
603 |
Normal saline solution |
Sodium chloride |
D02056 |
- |
- |
1件: 299 |
604 |
Normal saline: |
- |
- |
- |
- |
1件: 299 |
605 |
Norvir |
Ritonavir |
D00427 |
- |
- |
2件: 265, 299 |
606 |
Norvir 100 mg film-coated tablets |
Ritonavir |
D00427 |
- |
- |
1件: 299 |
607 |
Novo rapid |
- |
- |
- |
- |
1件: 299 |
608 |
Novo rapid insulin (novonordisk) |
- |
- |
- |
- |
1件: 299 |
609 |
Novolog insulin |
- |
- |
- |
- |
1件: 299 |
610 |
Novonorm 0.5 mg |
- |
- |
- |
- |
1件: 299 |
611 |
Novonorm 1 mg |
- |
- |
- |
- |
1件: 299 |
612 |
Novonorm 2 mg |
- |
- |
- |
- |
1件: 299 |
613 |
Novorapid / humalog short acting insulin |
- |
- |
- |
- |
1件: 299 |
614 |
Novorapid 100 u/ml, solution for injection in a vial. novorapid penfill 100 u/ml, solution for injection in a cartridge. novorapid flexpen 100 u/ml, solution for injection in a pre-filled pen. |
- |
- |
- |
- |
1件: 299 |
615 |
Novorapid aspartate |
Aspartic acid |
D00013 |
- |
- |
1件: 299 |
616 |
Noxafil® |
- |
- |
- |
- |
2件: 60, 299 |
617 |
Nutridrink-impact |
Topramezone |
- |
- |
- |
1件: 299 |
618 |
Nutropin aq |
- |
- |
- |
- |
4件: 78, 134, 193, 299 |
619 |
Nutropin aq [somatropin (dna origin) injection] |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
1件: 299 |
620 |
Ogt 918 |
- |
- |
- |
- |
2件: 19, 299 |
621 |
Oligog |
- |
- |
- |
- |
1件: 299 |
622 |
Oligog (60 mg/ml) |
- |
- |
- |
- |
1件: 299 |
623 |
Oligog cf-5/20 |
- |
- |
- |
- |
1件: 299 |
624 |
Oligog dpi |
- |
- |
- |
- |
1件: 299 |
625 |
Oligog dry powder for inhalation |
- |
- |
- |
- |
1件: 299 |
626 |
Oligog-cf5/20, alginate oligosaccharide (g-block) fragment |
Alginic acid |
D02324 |
- |
- |
1件: |